Elevated liver function tests in a patient on palbociclib and fulvestrant

Roberts, B

doi:10.12788/jcso.0437

Cited by 4 publications

(3 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the PALOMA 3 trial, grade 3 or higher hepatic adverse events included two cases of hepatic failure and one drug-induced liver injury in the palbociclib-fulvestrant arm [n = 345], while no such events were included in the comparator arm [n = 172] [19]. The increased risk of ALI reported here is consistent with imbalances in grade 3/4 ALT elevations in clinical trials, and has been hypothesized in recent reports [23][24][25][26]. Additionally, ribociclib and abemaciclib, the two other approved CDK4/6 inhibitors, carry hepatotoxicity warnings in their US package inserts, suggesting hepatotoxicity may be common to this class of medication [27,28].…”

Section: Discussionsupporting

confidence: 83%

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

et al. 2021

View full text Add to dashboard Cite

Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted. Results There were 2445 patients who initiated palbociclib including 566 new users of palbociclib-fulvestrant, and 2316 historical new users of fulvestrant monotherapy. Compared to these historical new users of fulvestrant monotherapy, new users of palbociclib-fulvestrant had a greater than 2-fold elevated risk for neutropenia, leukopenia, thrombocytopenia, stomatitis and mucositis, and ALI. Incidence of anemia and QT prolongation were more weakly associated, and incidences of serious infections and pulmonary embolism were similar between groups after propensity score matching. After adjustment for additional ALI risk factors, the elevated risk of ALI in new users of palbociclib-fulvestrant persisted (e.g. primary ALI algorithm hazard ratio (HR) = 3.0, 95% confidence interval (CI) = 1.1–8.4). Conclusions This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy. We observed an increased risk of ALI, extending clinical trial findings of significant imbalances in grade 3/4 elevations of alanine aminotransferase (ALT).

show abstract

Section: Discussionsupporting

confidence: 83%

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It was managed with alternative endocrine therapy after an attempt to withhold the medication or by initiating treatment with steroids. Rechallenge with palbociclib led to re-elevation of enzymes up to 10 times the upper limit of the normal range ( 11 – 14 ).…”

Section: Discussionmentioning

confidence: 99%

Palbociclib-induced severe hepatitis: A case study and literature review

Hyppolite

Hilzenrat

2021

CanLivJ

View full text Add to dashboard Cite

Palbociclib is a selective and reversible CDK4/6 inhibitor approved for patients presenting with HR+ HER2– locally advanced or metastatic breast cancer. Its adverse effect (AE) is mainly reported on the occurrence of leukopenia and fatigue. Even though palbociclib has an extensive hepatic metabolism, there are rare reports about significant liver toxicity. We present a 61-year-old female with metastatic breast cancer treated with palbociclib and an aromatase inhibitor (letrozole). The patient developed a rare AE of severe acute drug-induced hepatitis but improved dramatically after stopping the palbociclib and receiving treatment with N-acetylcysteine (NAC). The treatment with NAC may be a proof of concept for the mechanism of palbociclib liver injury.

show abstract

“…There has been one published report detailing two cases of pseudocirrhosis and liver-related death after 2-3 months of palbociclib therapy [5]. Another case report details elevated transaminases in a patient after three cycles of palbociclib [6]. Clinical trials of CDK4/6 inhibitors overall have shown rates of hepatotoxicity at less than 10%, and the lowest rates have come with palbociclib specifically, with Grade 3/4 elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) reported in 3.3 and 2.3% of all patients, respectively [7].…”

Section: Introductionmentioning

confidence: 99%

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

et al. 2020

View full text Add to dashboard Cite

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.

show abstract

Elevated liver function tests in a patient on palbociclib and fulvestrant

Cited by 4 publications

References 7 publications

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

Palbociclib-induced severe hepatitis: A case study and literature review

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

Contact Info

Product

Resources

About